Core Viewpoint - Deep Intelligence has completed a new round of financing amounting to $60 million, with total funding exceeding $100 million in just two months, indicating strong investor confidence in its AI-driven drug development capabilities [2][3]. Group 1: Financing and Investment - The new investors in this financing round include Xincheng Capital, Jinyi Capital, and KAITAI Capital, while existing shareholders such as Dinghui Baifu and New Ding Capital have also increased their stakes [2]. - The funds raised will primarily be used for upgrading the core technology system of the company [2]. Group 2: Technological Advancements - Deep Intelligence offers a full-stack intelligent solution for global pharmaceutical companies, covering all stages from preclinical research to post-marketing studies, unlike most companies that focus only on the preclinical phase [2][3]. - The company has achieved a breakthrough in its underlying technology architecture, which has contributed to its ability to attract continuous investment [3]. Group 3: AI Implementation in Drug Development - The company has developed a "bionic brain" composed of high-precision "Atomic Agents" that handle various tasks in the clinical research process, such as protocol design, statistical analysis, and regulatory compliance [4]. - The "bionic brain" operates through a closed-loop process of hypothesis-verification-reflection-correction, achieving an accuracy rate of over 99% in medical terminology [4][5]. Group 4: Self-Improving AI Systems - The system can automatically trigger reflection processes for attribution analysis, source tracing, and self-revision, allowing it to correct its own issues over time [5]. - Deep Intelligence has implemented a four-layer protective mechanism to address hallucination issues in AI models, achieving an industrial-grade accuracy of 99.9% [5]. Group 5: Innovations in Clinical Trials - The company has introduced a new Protocol Rehearsal AI that simulates virtual clinical trials to predict enrollment rates, dropout risks, and resource bottlenecks before actual patient recruitment [5]. - This innovation aims to accelerate the application of AI technology in human clinical trials, transforming drug development from a labor-intensive process to one focused on intelligent decision-making [5].

Core Insights - Deep Intelligence has recently completed a $60 million financing round, bringing its total funding to over $100 million in just two months, following a $50 million round in December [1] - The funds will primarily be used for upgrading the company's core technology system, which provides a full-stack intelligent solution for drug development, from preclinical research to post-market studies [1][4] Company Overview - Deep Intelligence offers a comprehensive AI-driven solution for pharmaceutical companies, enabling them to conduct clinical trials with high precision and efficiency, achieving a "zero revision" rate for clinical trial protocols approved by regulatory bodies [1][2] - The company has developed a "bionic brain" composed of high-precision "Atomic Agents" that handle various tasks in the clinical development process, ensuring scientific validity and compliance [2][3] Technological Advancements - The system incorporates a self-reflective process that allows for continuous improvement and error correction, enhancing the accuracy of medical terminology to over 99% [3] - A new Protocol Rehearsal AI has been introduced, which simulates clinical trials to predict outcomes and optimize resource allocation, potentially transforming the drug development process from labor-intensive to intelligent decision-making [3] Investor Perspectives - Investors express strong confidence in Deep Intelligence's ability to leverage AI in clinical research, highlighting its rapid iteration of AI capabilities and its potential to reshape industry cost structures and operational models [4][5] - The company is seen as a key player in the transition from labor-intensive to intelligence-driven drug development, with expectations for significant growth in the AI and healthcare sectors [4][5]